Market news
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.
Around 500 people, mostly tourists, are evacuated by boat from Agios Vasileios after becoming trapped.
Agios reports $44.7 million in Q2 mitapivat revenue and FDA priority review for sickle cell disease, while advancing pipeline diversification with cevidoplenib.
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +9.14% and +97.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (NASDAQ:AGIO) reported second-quarter 2026 mitapivat net revenue of $44.7 million, including $40.9 million in the United States and $3.8 million outside the U.S., as the company continued the U.S. thalassemia launch of AQVESME and prepared for a potential sickle cell disease ap
In July 2026, Agios Pharmaceuticals reported topline Phase 2 results for tebapivat in sickle cell disease, showing hemoglobin and hemolysis improvements but insufficient differentiation versus placebo, and consequently decided to discontinue tebapivat’s development for this use. At the same time, Agios highlighted that the FDA had already accepted its supplemental New Drug Application for mitapivat in sickle cell disease under Priority Review, keeping a PK activator path in this indication...
HRMY, ACAD, BIIB, INSM and AGIO are set to report Q2 results, with positive Earnings ESPs suggesting potential earnings surprises.
Detailed price information for Imunon Inc (IMNN-Q) from The Globe and Mail including charting and trades.
Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful differentiation.
This deals another blow to tebapivat’s development prospects following its May 2026 termination in MDS due to efficacy concerns.
Stock drops after development setbackAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares fell 14% on Tuesday after the company announced it will discontinue development of tebapivat for sickle cell disease following results from a Phase 2 clinical trial.
July 21 () - Agios Pharmaceuticals said on Tuesday it will stop development of its sickle cell disease treatment after results from a mid-stage trial did not establish a differentiated profile to support continued development. (Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore).
An accelerated approval for Agios' key drug to treat sickle cell disease appears to be on the cards.
Agios Pharmaceuticals (AGIO) is back in focus after the US Food and Drug Administration accepted its supplemental New Drug Application for mitapivat in sickle cell disease with Priority Review and set a PDUFA decision date of November 1, 2026. See our latest analysis for Agios Pharmaceuticals. Agios Pharmaceuticals' share price has moved sharply in recent weeks, with a 30 day share price return of 51.95% and a year to date share price return of 57.32%. By comparison, the 1 year total...
In early July 2026, Agios Pharmaceuticals announced that the U.S. FDA had accepted its supplemental New Drug Application for mitapivat in sickle cell disease under the accelerated approval pathway and granted it Priority Review, setting a PDUFA goal date of November 1, 2026, based on data from the RISE UP Phase 2 and Phase 3 trials. This step builds on mitapivat’s existing U.S. approvals in pyruvate kinase deficiency and thalassemia, underscoring Agios’s effort to extend its PK activator...
Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.
Agios Pharmaceuticals (AGIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Agios stock skyrocketed to a profit-taking zone Tuesday after the FDA assigned its sickle cell drug a speedy review.
This is the newest page. Registered accounts read further back.